Oric Pharmaceuticals (ORIC) Share-based Compensation (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Share-based Compensation came in at $6.9 million in Q1 2026, up 5.25% YoY from $6.6 million in Q1 2025, and up 9.88% on a QoQ basis from $6.3 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Share-based Compensation (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Share-based Compensation data on file, last reported at $6.9 million in Q1 2026.
- Quarterly Share-based Compensation rose 5.25% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 16.38% YoY) and the FY2025 annual result came in at $25.0 million, down 20.77% from the prior year.
- Share-based Compensation advanced to $6.9 million in Q1 2026, from $6.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.9 million in Q1 2026 to a low of $3.1 million in Q4 2022.
- A 5-year average of $4.8 million and a median of $5.0 million in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 43.77% in 2022, down 10.55% in 2022.
- Tracing ORIC's Share-based Compensation over 5 years: stood at $3.1 million in 2022, then rose by 25.34% to $3.9 million in 2023, then soared by 32.63% to $5.2 million in 2024, then climbed by 20.66% to $6.3 million in 2025, then grew by 9.88% to $6.9 million in 2026.
- The last three Share-based Compensation figures came in at $6.9 million (Q1 2026), $6.3 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | 7.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.09 Mn |
| Jun 30, 2026 | 7.09 Mn |
| Mar 31, 2026 | 6.90 Mn |
| Mar 31, 2026 | 6.90 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | 5.06 Mn |
| Sep 30, 2024 | 5.06 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Mar 31, 2024 | 4.96 Mn |